Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Metrochem Relugolix

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Relugolix

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 7,497Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 3Myfembree/Ryeqo

    02 3Orgovyx

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Myfembree/Ryeqo

    Relugolix

    arrow
    PharmaVenue
    Not Confirmed

    Brand Name : Myfembree/Ryeqo

    U.S.A
    arrow
    PharmaVenue
    Not Confirmed

    Dainippon Sumitomo

    Relugolix

    Main Therapeutic Indication : Women's Healthcare

    Currency : USD

    2021 Revenue in Millions : 8

    2020 Revenue in Millions : 0

    Growth (%) : New Launch in 2021

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Orgovyx

    Relugolix

    arrow
    PharmaVenue
    Not Confirmed

    Brand Name : Orgovyx

    U.S.A
    arrow
    PharmaVenue
    Not Confirmed

    Dainippon Sumitomo

    Relugolix

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 51

    2020 Revenue in Millions : 0

    Growth (%) : 100

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Orgovyx

    Relugolix

    arrow
    PharmaVenue
    Not Confirmed

    Brand Name : Orgovyx

    U.S.A
    arrow
    PharmaVenue
    Not Confirmed

    Dainippon Sumitomo

    Relugolix

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 160

    2021 Revenue in Millions : 51

    Growth (%) : 216

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Myfembree/Ryeqo

    Relugolix

    arrow
    PharmaVenue
    Not Confirmed

    Brand Name : Myfembree/Ryeqo

    U.S.A
    arrow
    PharmaVenue
    Not Confirmed

    Dainippon Sumitomo

    Relugolix

    Main Therapeutic Indication : Women's Health

    Currency : USD

    2022 Revenue in Millions : 25

    2021 Revenue in Millions : 8

    Growth (%) : 234

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Myfembree/Ryeqo

    Relugolix

    arrow
    PharmaVenue
    Not Confirmed

    Brand Name : Myfembree/Ryeqo

    U.S.A
    arrow
    PharmaVenue
    Not Confirmed

    Dainippon Sumitomo

    Relugolix

    Main Therapeutic Indication : Women's Health

    Currency : USD

    2023 Revenue in Millions : 60

    2022 Revenue in Millions : 32

    Growth (%) : 110

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Orgovyx

    Relugolix

    arrow
    PharmaVenue
    Not Confirmed

    Brand Name : Orgovyx

    U.S.A
    arrow
    PharmaVenue
    Not Confirmed

    Dainippon Sumitomo

    Relugolix

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 262

    2022 Revenue in Millions : 160

    Growth (%) : 86

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF